Compare GRPN & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GRPN | TBPH |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 714.1M | 824.9M |
| IPO Year | 2011 | 2013 |
| Metric | GRPN | TBPH |
|---|---|---|
| Price | $16.46 | $16.31 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $33.67 | $18.40 |
| AVG Volume (30 Days) | ★ 2.2M | 344.7K |
| Earning Date | 05-07-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 279.13 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,843,877,000.00 | $15,386,000.00 |
| Revenue This Year | $5.55 | $8.46 |
| Revenue Next Year | $6.63 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.17 | $10.42 |
| 52 Week High | $41.26 | $21.03 |
| Indicator | GRPN | TBPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.50 | 50.69 |
| Support Level | $16.05 | $16.07 |
| Resistance Level | $18.81 | $17.21 |
| Average True Range (ATR) | 1.70 | 0.32 |
| MACD | -0.41 | -0.02 |
| Stochastic Oscillator | 0.49 | 72.57 |
Groupon Inc is a globalised, scaled two-sided marketplace that connects consumers to merchants. Its categories include Local: local inventory includes things to do, beauty and wellness, food and drink, home and automotive services, online services, as well as other types of experiences and services. Goods: Includes merchandise across multiple product lines, such as electronics, sporting goods, jewelry, toys, household items and apparel, and Travel: Features travel experiences at both discounted and market rates, including hotels, airfare, and package deals covering both domestic and international travel. The company operates in two segments, North America and International, with the majority of revenue from the Local category from the North America Segment.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.